Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
Sponsor: ITB-Med LLC
Summary
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
Official title: A 60 Month, Single-arm, Proof-of-concept Study to Induce Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients Using Siplizumab, an Anti-CD2 Antibody in Combination With Cyclophosphamide and Splenectomy
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2022-06-29
Completion Date
2029-06
Last Updated
2024-11-27
Healthy Volunteers
No
Conditions
Interventions
TCD601
Investigational Product
Cyclophosphamide
Conditioning Regimen
TAC
Immunosuppression Therapy
MMF
Immunosuppression Therapy
Corticosteroids
Immunosuppression Therapy
Locations (1)
Karolinska University Hospital
Stockholm, Huddinge, Sweden